127 related articles for article (PubMed ID: 19636224)
1. Sunitinib-induced thyrotoxicosis.
Piñar D; Boix E; Meana JA; Herrero J
J Endocrinol Invest; 2009 Dec; 32(11):941-2. PubMed ID: 19636224
[No Abstract] [Full Text] [Related]
2. Response to 'Thyrotoxicosis during sunitinib treatment for renal cell carcinoma' by Grossmann et al.
Daniels GH
Clin Endocrinol (Oxf); 2009 Sep; 71(3):455. PubMed ID: 19138312
[No Abstract] [Full Text] [Related]
3. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Feldman DR; Martorella AJ; Robbins RJ; Motzer RJ
J Natl Cancer Inst; 2007 Jun; 99(12):974-5; author reply 976-7. PubMed ID: 17565156
[No Abstract] [Full Text] [Related]
4. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.
Grossmann M; Premaratne E; Desai J; Davis ID
Clin Endocrinol (Oxf); 2008 Oct; 69(4):669-72. PubMed ID: 18394019
[TBL] [Abstract][Full Text] [Related]
5. A case of pyoderma gangrenosum possibly associated with sunitinib treatment.
Ueharaguchi Y; Kabashima K; Sasahashi M; Matsuda A; Matubara K; Matsui M
Int J Dermatol; 2013 May; 52(5):634-6. PubMed ID: 23590380
[No Abstract] [Full Text] [Related]
6. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Garfield DH; Hercbergs A; Davis PJ
J Natl Cancer Inst; 2007 Jun; 99(12):975-6; author reply 976-7. PubMed ID: 17565154
[No Abstract] [Full Text] [Related]
7. A CT scan aspect of "hypodense thyroid gland" after sunitinib treatment for metastatic carcinoma of the kidney.
Vélayoudom-Céphise FL; Vian E; Bosewa T; Nallet E; Wemeau JL; Donnet JP
J Clin Endocrinol Metab; 2011 Mar; 96(3):590-1. PubMed ID: 21378222
[No Abstract] [Full Text] [Related]
8. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM
J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
Kalantari HR
Br J Cancer; 2009 Oct; 101(7):1222-3; author reply 1224. PubMed ID: 19755985
[No Abstract] [Full Text] [Related]
10. Sunitinib-induced thyrotoxicosis - a not so rare entity.
Jazvić M; Prpić M; Jukić T; Murgić J; Jakšić B; Kust D; Prgomet A; Bolanča A; Kusić Z
Anticancer Res; 2015 Jan; 35(1):481-5. PubMed ID: 25550591
[TBL] [Abstract][Full Text] [Related]
11. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma.
Flaig TW; Kim FJ; La Rosa FG; Breaker K; Schoen J; Russ PD
Invest New Drugs; 2009 Feb; 27(1):83-7. PubMed ID: 18563296
[No Abstract] [Full Text] [Related]
12. [Sunitinib-induced pyoderma gangrenosum].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2013 Dec; 140(12):841-2. PubMed ID: 24315238
[No Abstract] [Full Text] [Related]
13. Skin depigmentation induced by sunitinib treatment of renal cell carcinoma.
Al Enazi MM; Kadry R; Mitwali H
J Am Acad Dermatol; 2009 Nov; 61(5):905-6. PubMed ID: 19836653
[No Abstract] [Full Text] [Related]
14. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy.
van der Veldt AA; van den Eertwegh AJ; Hoekman K; Barkhof F; Boven E
Ann Oncol; 2007 Oct; 18(10):1747-50. PubMed ID: 17890217
[No Abstract] [Full Text] [Related]
15. Pyoderma gangrenosum with the use of sunitinib.
Nadauld LD; Miller MB; Srinivas S
J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
[No Abstract] [Full Text] [Related]
16. The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma.
Shinohara N; Takahashi M; Kamishima T; Ikushima H; Otsuka N; Ishizu A; Shimizu C; Kanayama H; Nonomura K
Br J Cancer; 2011 Jan; 104(2):241-7. PubMed ID: 21157447
[TBL] [Abstract][Full Text] [Related]
17. Cardiac tamponade in a patient treated by sunitinib for metastatic renal cell carcinoma.
Yıldız I; Varol U; Şen F; Kılıç L
Anadolu Kardiyol Derg; 2014 Nov; 14(7):654-6. PubMed ID: 25163084
[No Abstract] [Full Text] [Related]
18. [Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].
Fuertes Zamorano N; De Miguel Novoa MP; Molino González A; Díaz Pérez JÁ; Rojas-Marcos PM; Montañez Zorrilla MC
Endocrinol Nutr; 2010 Dec; 57(10):486-91. PubMed ID: 20702151
[TBL] [Abstract][Full Text] [Related]
19. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
[TBL] [Abstract][Full Text] [Related]
20. Acute cardiac failure after sunitinib.
Machiels JP; Bletard N; Pirenne P; Jacquet L; Bonbled F; Duck L
Ann Oncol; 2008 Mar; 19(3):597-9. PubMed ID: 18272908
[No Abstract] [Full Text] [Related]
[Next] [New Search]
